aschantin has been researched along with epidermal growth factor in 1 studies
| Studies (aschantin) | Trials (aschantin) | Recent Studies (post-2010) (aschantin) | Studies (epidermal growth factor) | Trials (epidermal growth factor) | Recent Studies (post-2010) (epidermal growth factor) |
|---|---|---|---|---|---|
| 5 | 0 | 4 | 24,155 | 217 | 4,699 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YY; Choi, KI; Dong, Z; Jang, JH; Lee, CJ; Lee, HS; Lee, JY; Lee, MH; Li, Y; Oh, SR; Ryu, HW; Surh, YJ | 1 |
1 other study(ies) available for aschantin and epidermal growth factor
| Article | Year |
|---|---|
Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
Topics: Animals; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lignans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |